Results 191 to 200 of about 38,595 (290)

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

iMetaMed, Volume 2, Issue 2, June 2026.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou, Jingwei Zhao, Yuqian Tang, Tan Liu, Zhiao Zhang, Ziheng Wang, Han Shen   +6 more
wiley   +1 more source

Improving nutritional assessment in GLP-1RA therapy: Beyond self-reports to equitable interventions. [PDF]

Obes Pillars
Aphale P, Shekhar H, Dokania S.
europepmc   +1 more source

Optimising GLP-1RA Efficacy: A Meta-Analysis of Baseline Age and HbA1c as Predictors of MACE Reduction in T2DM. [PDF]

Diabetes Metab Syndr Obes
Ghosal S, Ghosal A.
europepmc   +1 more source

Racial and demographic disparities in glp-1ra use among breast cancer patients with Type 2 Diabetes. [PDF]

NPJ Breast Cancer
Hundal J, Ashruf OS, Li H, Basen-Engquist K, Kaelber DC, Sukumar JS.   +5 more
europepmc   +1 more source

Spinal Implant–Associated Infection in Type 2 and Type 1 Diabetes: Phenotype‐Specific Inflammatory Features and Therapeutic Response to Semaglutide

JOR SPINE, Volume 9, Issue 2, June 2026.
ABSTRACT Background Diabetes mellitus (DM) is a major risk factor for postoperative infection and wound complications in spine surgery, yet distinctions between Type 2 (T2DM) and Type 1 (T1DM) pathophysiology are rarely addressed. This study compares infectious burden, wound healing, and immune response among a murine model of spinal implant‐associated
Thomas E. Olson, Trevor S. Lloyd, Christopher D. Hamad, Rene F. Chun, Joshua Wiener, Autreen Golzar, Joshua Mehany, Soroush Shahamatdar, Andrew Kittredge, Lauren Pearce, Kevin P. Francis, Farres Obeidin, Langston T. Holly, Michael R. Yeaman, John S. Adams, Nicholas M. Bernthal, William L. Sheppard   +16 more
wiley   +1 more source

Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists

JEADV Clinical Practice, Volume 5, Issue 2, Page 606-609, June 2026.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‑1 RAs) play a pivotal role in treating type 2 diabetes. Despite their widespread use, their dermatological manifestations remain under‐recognized, hence the interest of this systematic review. Objectives This systematic review aims to assess dermatological manifestations associated with
Nour Ghostine, Maya Halabi‐Tawil
wiley   +1 more source

Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes. [PDF]

Diabetes Care
Zhang D, Gencerliler N, Mukhopadhyay A, Blecker S, Grams ME, Wright DR, Wang VH, Rajan A, Butt E, Shin JI, Xu Y, Chhabra KR, Divers J.   +12 more
europepmc   +1 more source

GLP-1RA: New Hope in Obesity Therapy

Journal of Biosciences and Medicines
Danfeng Zhang, Hongyun Lu
openaire   +1 more source

Beyond BMI: The Impact of the New Lancet Commission Diagnostic Criteria on Prevalence of Obesity in the United States

Obesity, Volume 34, Issue S1, Page 29-42, June 2026.
ABSTRACT Objective This study compared population characteristics and overall US prevalence of obesity over time using the BMI criteria and the 2025 Lancet Commission criteria (i.e., the Excess Adiposity criteria). Methods We analyzed data from 58,053 adults aged ≥ 20 years in the National Health and Nutrition Examination Survey from 1999 to 2023.
Jennifer H. Hwang, Neda Laiteerapong
wiley   +1 more source

Information pharmacists assist in the construction of GLP-1RA prescription review rules in a tertiary hospital in China. [PDF]

BMC Health Serv Res
Zhou L, Duanmu W, Tan F, Gu X, Che H, Yin W.   +5 more
europepmc   +1 more source